ClinicalTrials.Veeva

Menu

ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis

University of Colorado Denver (CU Denver) logo

University of Colorado Denver (CU Denver)

Status

Enrolling

Conditions

Superior Cavo-Pulmonary Anastomosis
Pulmonary Vascular Resistance Abnormality
Metabolomics
Single-ventricle
Endothelin

Treatments

Other: Research Blood Sampling

Study type

Observational

Funder types

Other

Identifiers

NCT03404258
17-0832

Details and patient eligibility

About

This is a novel preliminary study of biomarkers of pathologic pre-operative pulmonary vascular development, elevated pre-operative Pulmonary Vascular Resistance Index (PVRi), and complications associated with decreased post-operative pulmonary blood flow in single ventricle patients undergoing superior cavo-pulmonary anastomosis (SCPA). The study will utilize a combined targeted and untargeted approach to both optimize translation of a promising existing biomarker and efficiently identify novel biomarkers and potential therapeutic targets in this population.

Full description

Overall Hypothesis: Endothelin-1 (ET1) and associated dysregulation of key metabolic pathways decrease pre-operative pulmonary blood vessel development and increase post-operative pulmonary blood vessel resistance leading to decreased pulmonary blood flow in patients undergoing SCPA.

For enrolled patients, collected data will include:

  • 3 mL blood sample (x2) at pre-SCPA catheterization.
  • 3 mL blood samples at 2, 24, and 48 hours post-operative.
  • Urine sample pre-operatively and post-operatively
  • Collection of otherwise-discarded operative tissue sample from the pulmonary artery.
  • Collection of clinical data, demographic data, and results of routine, post-operative hemodynamic monitoring.

Enrollment

50 estimated patients

Sex

All

Ages

1 month to 2 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Congenital heart disease patients undergoing catheterization for pre-SPCA evaluation or undergoing SCPA without plans for cardiac catheterization (utilizing data from a previously performed clinical catheterization).
  • All patients will have age from 31 days to 2 years.

Exclusion criteria

  • Patients who will remain post-op with a pulsatile source of pulmonary blood flow in addition to the cavo-pulmonary anastomosis (so called "1.5 ventricle" repair) will be excluded.
  • Due to limitations in acceptable sample blood volumes for research, patients with weight <4kg will be excluded.
  • Patients will not be excluded on the basis of gender, ethnicity, genetic diagnosis, gestational age at birth, non-cardiac comorbidity, or pre-operative medication regimen.

Trial design

50 participants in 2 patient groups

Study Patients
Description:
Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
Treatment:
Other: Research Blood Sampling
Control Patients
Description:
Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
Treatment:
Other: Research Blood Sampling

Trial contacts and locations

1

Loading...

Central trial contact

Jesse Davidson, MD; Benjamin Frank, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems